Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liothyronine in Multiple Sclerosis
NCT02506751Phase 1Completed
- Sponsor
- Johns Hopkins University
- Start
- Jul 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of liothyronine in multiple sclerosis (MS), sponsored by Johns Hopkins University. Primary endpoint: Incidence rate of adverse events at 26 weeks. Started Jul 2015; status: completed.
02
Drugs
liothyronine
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02506751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02506751.